Core Points - Transgene has requested a suspension of trading for its shares on Euronext Paris pending the publication of results from its capital increase [1] - Trading is expected to resume on November 27, 2025, at the market opening [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment [2] - The company's lead candidate, TG4050, is an individualized treatment that has shown clinical proof of concept in patients with head and neck cancer [2] - Transgene is also developing other candidates, including BT-001, which is based on a patented oncolytic virus [2] Technology Platforms - The myvac® platform allows for patient-specific immunotherapy by integrating tumor mutations identified through artificial intelligence [3] - The invir.IO® platform enables the design of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [3]

Core Viewpoint - Scilex Holding Company has successfully closed the exercise of existing warrants, generating approximately $20.3 million in gross proceeds, which will be used for working capital and general corporate purposes [1][4]. Group 1: Warrants and Proceeds - The company exercised two sets of existing warrants, totaling 904,396 shares, at a reduced exercise price of $22.51 per share [1]. - The April 2024 Warrants were originally priced at $38.50 per share, while the December 2024 Warrants had an exercise price of $22.72 per share [1]. - The gross proceeds from the exercise of these warrants were approximately $20.3 million before deducting fees and expenses [1]. Group 2: New Warrant Issuance - In exchange for the immediate cash exercise of the existing warrants, the company issued a new unregistered warrant for 1,356,594 shares at an exercise price of $29.00 per share, which is exercisable immediately and has a five-year term [3]. - The new warrant was offered in a private placement under Section 4(a)(2) of the Securities Act and Regulation D [5]. Group 3: Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [8]. - The company's commercial products include ZTlido, ELYXYB, and Gloperba, which target significant unmet medical needs [9][10]. - Scilex has three product candidates in development, including SP-102, SP-103, and SP-104, which are aimed at various pain management indications [10].

Group 1 - Townsquare Media, Inc. will participate in Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference on December 3, 2025, at 1:30 PM Eastern Time [1] - Interested investors can attend the conference at a discounted rate using the code TSQNOBLECON [2] - A high-definition video webcast of the presentation will be available the following day on Townsquare's investor relations page and will be archived for 90 days [3] Group 2 - Townsquare Media is a community-focused digital and broadcast media and digital marketing solutions company, primarily targeting markets outside the top 50 in the U.S. [4] - The company operates Townsquare Ignite, a digital advertising division that utilizes proprietary technology and a portfolio of over 400 local news and entertainment websites [4] - Townsquare Interactive provides subscription digital marketing services to small and medium-sized businesses, offering a range of digital services including website design and search engine optimization [4] Group 3 - Noble Capital Markets, established in 1984, is a full-service broker-dealer providing investment and advisory services, with a focus on middle-market expertise [5] - Noble has raised billions of dollars for companies and published over 45,000 equity research reports [5] - Channelchek, launched by Noble in 2018, is an investor community dedicated to public emerging growth companies, offering free access to institutional-quality research [6]

Core Insights - EXL is hosting its second annual IdeaTank event on December 8, 2025, at the Nasdaq MarketSite, showcasing innovation and AI-driven solutions from its global employee base [2][4] - The 2025 IdeaTank has received over 11,000 submissions, marking a seven-fold increase from the previous year, highlighting the growing engagement and creativity within the company [3][5] - Winning ideas from the IdeaTank will receive funding and development resources to enhance EXL's capabilities and client solutions [2][5] Company Overview - EXL is a global data and AI company that focuses on transforming business models and driving growth through innovative solutions across various industries, including insurance, healthcare, and banking [8] - The company was founded in 1999 and has approximately 63,000 employees worldwide, emphasizing core values such as innovation, collaboration, and excellence [8] Event Highlights - The IdeaTank event will feature Robert Herjavec, a recognized entrepreneur, who will engage with finalists and discuss entrepreneurship and innovation [4][6] - This year's submissions cover a wide range of themes, including AI applications in medical data and enhancements to existing EXL capabilities [5] - Finalists will have the opportunity to pitch their ideas in person, receiving strategic support and mentorship to bring their concepts to fruition [5][6]

Core Insights - PetVivo.ai has launched an AI platform aimed at transforming the $150 billion pet care market by significantly reducing customer acquisition costs for veterinary practices [2][4][9] Group 1: Company Overview - PetVivo Holdings, Inc. is focused on commercializing innovative medical products and therapeutics for companion animals and horses [2][12] - The company has introduced PetVivo.ai, an AI-driven Software-as-a-Service (SaaS) platform that enhances its existing product portfolio [3][10] Group 2: Market Opportunity - The pet care industry exceeds $150 billion annually, with Gen Z and Millennial pet parents making up 57% of pet owners, who expect modern digital experiences [4][8] - There are approximately 30,000 veterinary practices in the U.S. and over 100,000 worldwide, indicating a large and under-digitized market for PetVivo.ai [8] Group 3: Product and Technology - PetVivo.ai utilizes nine specialized AI agents to connect veterinary practices with pet owners, improving lead generation and customer engagement [5][10] - The platform has demonstrated a customer acquisition cost of $42.53, significantly lower than the typical $80–$400 spent by veterinary practices [2][7] Group 4: Financial Metrics - In a beta program, the median practice acquired 47 new clients over six months, achieving a blended customer acquisition cost of $42.53 [5][7] - The platform offers a pricing model starting at $1,999 per month, with gross margins between 80% and 90% [7] Group 5: Competitive Advantages - PetVivo.ai holds a first-mover advantage in the AI-driven veterinary market, with no direct competitors and strong network effects [10] - The company has established relationships with 1,200 veterinary clinic distributors and plans to expand to over 7,000 [10] Group 6: Valuation Potential - The launch of PetVivo.ai is expected to transition the company from traditional medical device revenue multiples (1–2x) to AI SaaS multiples (15–30x), indicating potential valuation upside [9]

Core Points - Transgene is launching a fundraising initiative to raise approximately €105 million through the issuance of new shares to specialized investors via private placement and to retail investors via the PrimaryBid platform [1][4][6] - The funds raised will primarily accelerate the development of the myvac® program, which focuses on individualized cancer vaccines, particularly for head and neck cancer [3][4][7] - The company anticipates that the net proceeds from the fundraising, combined with existing cash, will be sufficient to meet working capital requirements until early 2028 [5][9] Fundraising Details - The fundraising consists of a private placement aimed at international institutional investors and a public offering for retail investors, with TSGH committing to subscribe for at least €70 million [6][10] - A concurrent capital increase of approximately €39.4 million is reserved for TSGH, which will be executed at the same price as the private placement and PrimaryBid offering [2][32] - The private placement and PrimaryBid offering are expected to close on 26 November 2025, with trading of Transgene shares suspended on that day [6][29][20] Use of Proceeds - Approximately 70% of the net proceeds will be allocated to accelerate the myvac® program, including ongoing clinical trials and manufacturing optimization [7][4] - About 20% will be used for R&D costs related to the myvac® program and other clinical trials, while the remainder will cover general administrative expenses [7][4] Financial Position - Prior to the fundraising, Transgene had €11.1 million in cash and a drawing capacity of €8.7 million on the Current Account Advance [8] - Following the completion of the Reserved Capital Increase, the Current Account Advance Agreement will be terminated, enhancing the company's financial stability [9][32] Expected Milestones - Key milestones for the myvac® platform include reporting important data in 2026 and 2027, with potential initiation of a Phase 3 trial in head and neck cancer [3][11][13]

Core Insights - MAX Power Mining Corp. is hosting a news conference on November 27, 2025, to discuss its recent achievements in the Natural Hydrogen sector [1][2] - The company has successfully drilled Canada's first dedicated Natural Hydrogen well at the Lawson target on the Genesis Trend, marking a significant milestone in the industry [2][4] - MAX Power holds approximately 1.3 million acres (521,000 hectares) of permits in Saskatchewan, positioning itself as a leader in the Natural Hydrogen exploration market [4] Company Overview - MAX Power is focused on mineral exploration, particularly in the context of North America's transition to decarbonization [4] - The company is actively engaged in the Natural Hydrogen sector and has confirmed the presence of Natural Hydrogen and helium in multiple horizons at its Lawson target [4] - In addition to its Canadian operations, MAX Power has a portfolio of properties in the United States and Canada that focus on critical minerals, including a lithium discovery at the Willcox Playa Lithium Project in Arizona [4] Leadership and Future Plans - The news conference will feature key executives, including CEO Mansoor Jan and incoming CEO Ran Narayanasamy, who will take over in early December 2025 [3] - The company is currently in the "Analytic Phase" following the drilling of the Natural Hydrogen well, with plans for a "Completion Test Phase" to follow [4]

Company Overview - SKK Holdings Limited is a civil engineering service provider specializing in subsurface utility works in Singapore, with over 10 years of experience in public utility projects including power and telecommunication cable laying, water pipeline works, and sewer rehabilitation [5] Annual General Meeting (AGM) - SKK Holdings will hold its 2025 Annual General Meeting of Shareholders on December 17, 2025, at 10 a.m. Singapore Time [1] - Shareholders listed in the register at the close of business on November 21, 2025, are entitled to receive notice and vote at the AGM [2] Financial Reporting - The company has filed its annual report on Form 20-F, including audited financial statements for the financial year ended December 31, 2024, with the U.S. Securities and Exchange Commission [4] - The Form 20-F and additional financial documents are accessible on the company's website and the SEC's website [4][3]

Core Insights - Provident Bank and The Provident Bank Foundation have launched a Crisis Response Fund to support nonprofit organizations addressing food insecurity amid rising demand [1][2] - The initiative involves a joint investment of $50,000, with $10,000 grants awarded to five nonprofit organizations providing essential food access programs [2][3] - The fund aims to provide immediate assistance to nonprofits in specific counties, helping them meet increased demand for meals and groceries, particularly due to funding gaps from the recent U.S. government shutdown [2][4] Company Overview - Provident Bank, founded in 1839, is the oldest community-focused financial institution in New Jersey, with assets totaling $24.83 billion as of September 30, 2025 [6] - The bank operates over 140 branches across New Jersey and parts of New York and Pennsylvania, offering a range of financial solutions and services [6][8] Nonprofit Support - The Crisis Response Fund will support organizations such as The Salvation Army, Franklin Food Bank, Jewish Family & Children's Service, Jewish Family Service of the Lehigh Valley, and Bayonne Economic Opportunity Foundation [3][7] - These organizations provide critical services, including meal distribution and food assistance, to vulnerable populations, highlighting the urgent need for support in the community [4][7] Foundation Mission - The Provident Bank Foundation, established in 2003, focuses on supporting nonprofit organizations that foster strong, inclusive communities through grants in Education, Human Services, and Workforce Development [9] - Since its inception, the Foundation has awarded over $30 million to organizations that drive meaningful community change [9]

Core Points - QNB Corp. declared a quarterly cash dividend of $0.38 per share, payable on December 26, 2025, to shareholders of record on December 12, 2025 [1] Company Overview - QNB Corp. operates commercial and retail banking services through its subsidiary, QNB Bank, with twelve banking offices located in Bucks, Montgomery, and Lehigh Counties [2] - The company's stock is traded in the over-the-counter QX market under the symbol "QNBC" [2]